ArticleThe Journal of pharmacology and experimental therapeutics2020
Pharmacological Properties of
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- The delta-opioid receptor: a therapeutic target for Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
- Biasing G protein βγ subunit downstream signaling enhances the analgesic effects of endogenous opioid receptor agonists during nitroglycerin-induced thermal hypersensitivity.Molecular pharmacology · 2025Article
- Delta opioid receptors: Overlooked outlier or the next big thing.Current opinion in pharmacology · 2025Review
- Receptor expression and signaling properties in the brain, and structural ligand motifs that contribute to delta opioid receptor agonist-induced seizures.Neuropharmacology · 2023Review
- Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice.The Journal of pharmacology and experimental therapeutics · 2023Article
- Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy.Frontiers in pharmacology · 2023Article
- Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions.Frontiers in pharmacology · 2022Article
- Review
- Targeting the mu-Opioid Receptor for Cancer Treatment.Current oncology reports · 2021Review
- Adenosine Receptor Reserve and Long-Term Potentiation: Unconventional Adaptive Mechanisms in Cardiovascular Diseases?International journal of molecular sciences · 2021Review
- Reply to Zhuang et al.: Potential side effects of positive allosteric modulators of the mu-opioid receptor.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Peripherally Acting Opioids in Orofacial Pain.Frontiers in neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Isaac J DrippsDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Ruizhuo ChenDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Amanda M ShaferDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Kathryn E LivingstonDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Alexander DisneyDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Stephen M HusbandsDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
John R TraynorDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Kenner C RiceDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.).
Emily M JutkiewiczDepartment of Pharmacology and Edward F Domino Research Center, University of Michigan Medical School, Ann Arbor, Michigan (I.J.D., R.C., A.M.S., K.E.L., J.R.T., E.M.J.); Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.); and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland (K.C.R.) ejutkiew@umich.edu.
National Institute on Drug Abuse · USUniversity of Michigan–Ann Arbor · USNational Institute on Alcohol Abuse and Alcoholism · US
Funding
Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid ReceptorsZIADA000527 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2025
$23.2MAllosteric Modulation of the Mu-Opioid ReceptorR37DA039997 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TRAYNOR, JOHN R. · 2015 to 2024
$6.4MNarcotic Drug and Opioid Peptide Basic Research projectP01DA000254 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOODS, JAMES H · 2003 to 2006
$5.0MDISCOVERY OF NEW TREATMENTS FOR INTRAVENOUS DRUG ABUSER01DA007315 · NIDA · UNIVERSITY OF BRISTOL · PI HUSBANDS, STEPHEN M, TRAYNOR, JOHN R. · 1991 to 2019
$4.8MRegulator of G protein signaling proteins differentially control opioid analgesiaR01DA035316 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TRAYNOR, JOHN R. · 2014 to 2018
$2.7MEndogenous enkephalins and reward mechanismsR01DA042092 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JUTKIEWICZ, EMILY M · 2017 to 2021
$1.6MNIDA NIH HHS P01 DA000254NIDA NIH HHS R01 DA007315NIDA NIH HHS R01 DA035316NIDA NIH HHS R01 DA042092NIDA NIH HHS R37 DA039997
Abstract
δ-Opioid receptor (
Indexed as
AnimalsBehavior, AnimalBenzamidesBuprenorphineDrug Partial AgonismMiceNaltrexonePiperazinesReceptors, Opioid, delta4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamideBenzamidesBU 48BuprenorphineNaltrexonenaltrindolePiperazinesReceptors, Opioid, delta
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.